Medical News

RSS

Trimeris, Roche collaborate to commercialize FUZEON product

Trimeris, Inc., announced today that the Company and its partner, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., have entered into an agreement relieving Trimeris of any obligation to repay certain deferred marketing expenses.

28 Sep 2010

Study confirms Artelon Cosmetic can treat patients with tissue defects

A post-market study has been conducted by the Brånemark Clinic in Gothenburg on Artelon Cosmetic for soft tissue augmentation in the upper jaw. The study confirms that patients with tissue defects can be treated successfully with Artelon Cosmetic.

28 Sep 2010

GATC Biotech to apply Illumina's HiSeq 2000 for human genome analysis

Within the next four years GATC Biotech plans to analyse 100,000 human genomes in particular for the pharmaceutical and diagnostic industry as well as for academic research. This will be realised by applying Illumina's HiSeq 2000 as well as GATC Biotech's latest acquisition, the single molecule sequencing platform PacBio RS.

28 Sep 2010

GenMark’s eSensor technology selected for Warfarin clinical study

GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, announced today that their eSensor Warfarin Sensitivity Test has been selected for use in a new pivotal Warfarin clinical study the WARFARIN Trial.

28 Sep 2010

HCC report supports implementation of medical imaging guidelines for physicians

The Canadian Association of Radiologists (CAR) recently contributed to a report produced by the Health Council of Canada (HCC) entitled “Decisions, Decisions: Family Doctors as Gatekeepers in the Use of Prescription Drugs and Diagnostic Imaging in Canada.” This report, which was released today, supports one of the CAR’s main objectives: to implement medical imaging guidelines at a national level to guide physicians in selecting the most effective diagnostic imaging exam the first time.

28 Sep 2010

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.

28 Sep 2010

ETP Nanomedicine forum to take place in Italy on 14 and 15 October 2010

The 5th General Assembly & Annual Forum of the European Technology Platform on Nanomedicine will take place at Centro Congressi Fondazione Cariplo in Milan, Italy on 14 and 15 October 2010.

28 Sep 2010

Study establishes link between swearing and pain tolerance

While swearing is often a common response to pain, Richard Stephens and his colleagues, John Atkins and Andrew Kingston, were surprised to discover that no links had been established between swearing and the actual experience of physical pain.

28 Sep 2010

Venous thromboembolism drugs to experience robust growth by 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and widespread uptake of novel oral anticoagulants, the combined markets for drugs used in the treatment and prophylaxis of venous thromboembolism will experience robust growth, increasing from $2.9 billion in 2009 to more than $5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

28 Sep 2010

Routine, short bouts of exercise can increase fitness levels

Trying to get fit but can't work it into your daily schedule? Incorporating even relatively short bouts of exercise into a daily commute appears to deliver significant rewards, according to a new study from the University of North Carolina at Chapel Hill.

28 Sep 2010

Researchers use biological weapon to fight salmon parasite

A few years ago, fish farms in Chile produced enormous numbers of salmon. Now the industry is on its knees as a result of several years of disease and devastation by lice.

28 Sep 2010

Study reveals hunger costs Minnesotans $1.62 billion per annum

A University of Minnesota Food Industry Center study funded by Target and released today reveals that hunger is costing Minnesotans upwards of $1.62 billion annually in direct and indirect health and education costs. The Cost/Benefit Study also suggests that interventions aimed at preventing hunger are sound moral, social and financial investments.

28 Sep 2010

Humans have similar immune system like plants

In addition to known antiviral agents such as antibodies and interferons, people also seem to have a similar immune system to that previously identified in plants. This is the result of research carried out by Esther Schnettler at Wageningen University.

28 Sep 2010

Researchers develop microelectronic circuitry to guide axon growth in damaged brain

Researchers in the Midwest are developing microelectronic circuitry to guide the growth of axons in a brain damaged by an exploding bomb, car crash or stroke. The goal is to rewire the brain connectivity and bypass the region damaged by trauma, in order to restore normal behavior and movement.

28 Sep 2010

Children with food allergies experience bullying: Study

In the first ever study to assess the social impact of food allergies in children, Mount Sinai researchers have found that approximately 35 percent of children with food allergies, who are over the age of five, were reported to have experienced bullying, teasing, or harassment as a result of their allergies.

28 Sep 2010

Study indicates majority of children suffering from chronic headache may outgrow the condition

Most children who suffer from chronic daily headache may outgrow the disabling condition, according to research published in the July 15, 2009, online issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

28 Sep 2010

African-Americans less likely to ban smoking at home

Prohibiting tobacco use at home could reduce adolescent smoking rates, but the practice might be less common in black families than in white ones, a new study found.

28 Sep 2010

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company's Mimopath technology in oral vaccines to prevent and treat severe diarrhea.

28 Sep 2010

VENT Study highlights endobronchial approaches to emphysema treatment

Pulmonx, an emerging leader in interventional pulmonology, announced today that the New England Journal of Medicine has published the results of the largest prospective, randomized, controlled study completed to date of endobronchial approaches to emphysema treatment, the VENT Study (Endobronchial Valve for Emphysema PalliatioN Trial).

28 Sep 2010

Suicide rates high among middle-aged people

The suicide rate for middle-aged people - a group considered relatively protected from suicide and with historically stable suicide rates - took an upward jump between 1999 and 2005, according to research by sociologists Ellen Idler of Emory University and Julie Phillips of Rutgers University.

28 Sep 2010